NCT00510874View on ClinicalTrials.gov

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

780

Participants

Timeline

Start Date

July 28, 2007

Primary Completion Date

June 17, 2008

Study Completion Date

October 24, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

Pumarix™

Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

BIOLOGICAL

Pandemrix ™

Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Trial Locations (10)

30281

GSK Investigational Site, Stockbridge

33143

GSK Investigational Site, Miami

35802

GSK Investigational Site, Huntsville

59801

GSK Investigational Site, Missoula

66219

GSK Investigational Site, Lenexa

89104

GSK Investigational Site, Las Vegas

92801

GSK Investigational Site, Anaheim

B3K 6R8

GSK Investigational Site, Halifax

B2N 1L2

GSK Investigational Site, Truro

J1H 4J6

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00510874 - Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults | Biotech Hunter | Biotech Hunter